No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
839 |
4. Check minimum number of eventsNone |
839 |
5. Include endpointsNone |
839 |
6. Filter based on genotype QC (FinnGen only) |
804 |
Control definitions (FinnGen only)
- Control exclude
- AB1_MYCOSES
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Other superficial mycoses
based on the number of shared cases.
Similar with more cases:
- Other superficial mycoses
- Mycoses
- Mycoses
- Certain infectious and parasitic diseases
- Certain infectious and parasitic diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5932 | 2806 | 3076 |
| Only index persons | 5363 | 2569 | 2794 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.08 | 0.09 |
| Only index persons | 0.10 | 0.09 | 0.11 |
| Median age at first event (years) | |||
| Whole population | 38.43 | 39.96 | 37.05 |
| Only index persons | 37.82 | 39.40 | 36.37 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 804 | 414 | 390 |
| Unadjusted period prevalence (%) | 0.16 | 0.15 | 0.18 |
| Median age at first event (years) | 45.76 | 42.78 | 48.93 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 839
- Matched controls
- 8390
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
B36.0
ICD-10 Finland
Pityriasis versicolor
477.5
307.7
625
51
J02AC02
ATC
itraconazole; systemic
3.6
55.0
237
834
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.9
53.9
133
312
J02AB02
ATC
ketoconazole; oral
8.2
51.2
71
94
B36.9
ICD-10 Finland
Superficial mycosis, unspecified
66.3
43.7
50
8
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.1
43.5
241
972
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.9
42.0
259
1107
B36.8
ICD-10 Finland
Other specified superficial mycoses
56.4
40.9
48
9
H62.2*B36.9
ICD-10 Finland
Otomycosis NOS
+∞
31.4
30
*
XQ848
NOMESCO Finland
Dermatological photography
6.4
30.0
51
84
E0000UV, ,
ATC
2.2
27.3
391
2377
11100
ICD-8 Finland
Dermatomycosis, other and unspecified, Pityriasis versicolor
+∞
22.0
21
*
B35.3
ICD-10 Finland
Tinea pedis
4.5
20.9
53
125
127
Kela drug reimbursment
Transplant complication
7.1
20.5
31
45
L04AX03
ATC
methotrexate; systemic
2.8
20.2
110
427
L04AX01
ATC
azathioprine; systemic
4.2
20.1
56
142
D07AC01
ATC
betamethasone; topical
2.0
20.0
321
1979
L04AD01
ATC
ciclosporin; systemic
6.2
17.9
31
52
L01BA01
ATC
methotrexate; systemic
4.4
17.8
45
106
D01AC02
ATC
miconazole; topical
3.0
17.3
80
283
L04AA06
ATC
mycophenolic acid; systemic
5.7
17.1
32
58
11199
ICD-8 Finland
Dermatomycosis, other and unspecified, Unspecified
+∞
16.7
16
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
2.5
16.5
109
465
L40.0
ICD-10 Finland
Psoriasis vulgaris
3.8
16.5
51
140
B36
ICD-10 Finland
Other superficial mycoses
30.7
16.2
21
7
L04AA01
ATC
[U] ciclosporin
11.5
15.3
28
25
J02AC01
ATC
fluconazole; systemic
1.8
15.1
327
2176
TQW80
NOMESCO Finland
Local dermatologic skincare
4.7
14.8
34
74
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
3.1
14.7
62
208
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
4.0
14.6
42
109
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
14.6
351
2403
D01AE15
ATC
terbinafine; topical
2.9
14.1
70
258
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
5.2
13.7
28
55
D07AC13
ATC
mometasone; topical
1.8
13.5
240
1494
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.5
13.1
84
352
D01BA02
ATC
terbinafine; oral
1.9
13.0
212
1281
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.4
12.8
92
408
1110A
ICD-9 Finland
Dermatomycosis, other and unspecified, Pityriasis versicolor
+∞
12.5
12
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.2
12.3
50
164
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.0
12.1
158
885
L04AB04
ATC
adalimumab; parenteral
4.1
12.0
33
83
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
3.7
12.0
38
106
H02AB04
ATC
methylprednisolone; systemic
2.1
11.9
118
598
R21
ICD-10 Finland
Rash and other nonspecific skin eruption
3.1
11.8
49
163
J01FF01
ATC
clindamycin; systemic
1.8
11.6
220
1388
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.8
11.5
212
1326
S29
ICPC
Skin symptom/complaint other
1.9
11.4
154
871
B35.1
ICD-10 Finland
Tinea unguium
2.8
11.1
57
214
A02BC02
ATC
pantoprazole; systemic
1.7
11.1
526
4217
D02AE01
ATC
carbamide; topical
2.7
11.0
60
232
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
4.6
11.0
26
58
N02AX02
ATC
tramadol; systemic, rectal
1.7
10.9
333
2388
Z94.0
ICD-10 Finland
Kidney transplant status
9.0
10.8
22
25
B35.6
ICD-10 Finland
Tinea inguinalis [Tinea cruris]
4.7
10.8
25
55
A07EC01
ATC
sulfasalazine; oral, rectal
2.4
10.7
76
335
EJA10
NOMESCO Finland
Biopsy of tongue or floor of mouth
5.4
10.6
21
40
XQ845
NOMESCO Finland
Dermatoscopy
5.1
10.6
22
44
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
1.9
10.4
158
927
H02AB06
ATC
prednisolone; systemic
1.6
10.4
363
2683
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.1
10.3
109
565
D07AB02
ATC
hydrocortisone butyrate; topical
1.7
10.3
239
1590
D07AD01
ATC
clobetasol; topical
2.0
10.3
130
719
XQ802
NOMESCO Finland
Epicutan test
3.1
10.2
43
144
XQ800
NOMESCO Finland
Prick test
2.4
9.9
70
307
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.3
9.9
75
340
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.7
9.8
212
1379
J01DB01
ATC
cefalexin; oral
1.8
9.8
688
6008
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
3.8
9.8
30
82
L04AD02
ATC
tacrolimus; systemic
7.5
9.7
22
30
B35.4
ICD-10 Finland
Tinea corporis
5.4
9.7
19
36
L21.8
ICD-10 Finland
Other seborrhoeic dermatitis
5.4
9.7
19
36
S02
ICPC
Pruritus
3.2
9.6
37
118
J45.9
ICD-10 Finland
Asthma, unspecified
1.9
9.6
145
850
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.1
9.5
94
475
TK800
NOMESCO Finland
Hemodialysis
4.2
9.5
25
61
TPH04
NOMESCO Finland
Cathetrisation of vein
1.8
9.4
166
1018
L17
ICPC
Foot/toe symptom/complaint
1.7
9.3
222
1482
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
2.2
9.1
82
399
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
9.2
9.1
18
20
WZC00
NOMESCO Finland
Treatment plan or consultation
1.6
8.9
291
2097
J01MA02
ATC
ciprofloxacin; systemic
1.6
8.8
278
1986
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
8.8
174
1102
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.2
8.6
75
360
L21.9
ICD-10 Finland
Seborrhoeic dermatitis, unspecified
4.1
8.6
23
57
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
1.9
8.6
116
655
K13.79
ICD-10 Finland
Change in the oral mucosa UNS
3.6
8.5
27
76
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
2.3
8.5
64
290
N05CF01
ATC
zopiclone; oral
1.6
8.3
227
1563
B07.9
ICD-10 Finland
Verruca simplex
3.0
8.3
37
129
D01AC03
ATC
econazole; topical
2.5
8.2
53
223
XG410
NOMESCO Finland
Flow-volume spirometry
3.0
8.2
36
124
WX408
NOMESCO Finland
General anesthesy, balanced
1.7
8.2
199
1330
UKC02
NOMESCO Finland
Cystoscopy
1.9
8.2
104
575
L04AA11
ATC
[U] etanercept
17.4
8.1
12
7
SPAT1144
SPAT
Treatment of reopened or infected surgical wound
2.4
8.0
54
232
B37.08
ICD-10 Finland
Other candidal stomatitis
22.3
8.0
11
5
D01AE16
ATC
amorolfine; topical
2.0
7.9
83
429
A01AB09
ATC
miconazole; local oral
2.2
7.9
64
299
UGC12
NOMESCO Finland
Flexible bronchoscopy
2.4
7.8
53
229
XKD00
NOMESCO Finland
Uroflowmetry
1.9
7.8
102
569
S97
ICPC
Chronic ulcer skin
2.6
7.8
45
180
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.5
7.8
288
2122
R50.9
ICD-10 Finland
Fever, unspecified
1.8
7.8
122
721
ZXC50
NOMESCO Finland
Cryotherapy
3.6
7.7
25
71
H60.3
ICD-10 Finland
Other infective otitis externa
3.3
7.7
28
86
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.2
7.7
65
309
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.5
7.6
339
2597
SPAT1263
SPAT
Sampling
1.5
7.6
319
2413
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
4.2
7.6
20
49
L12
ICPC
Hand/finger symptom/complaint
1.8
7.5
132
808
R03BB04
ATC
tiotropium bromide; inhalant
2.1
7.4
69
340
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
1.8
7.4
108
623
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
2.4
7.4
50
216
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
1.9
7.3
92
506
11180
ICD-8 Finland
Dermatomycosis, other and unspecified, Erythrasma mycoides
+∞
7.3
7
*
L30.0
ICD-10 Finland
Nummular dermatitis
2.7
7.2
37
139
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
2.9
7.2
34
122
N03AX16
ATC
[U] pregabalin
1.6
7.2
168
1107
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
2.2
7.1
58
271
J01MA12
ATC
levofloxacin; systemic
1.8
7.1
125
763
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
4.1
7.1
19
47
J45.1
ICD-10 Finland
Nonallergic asthma
2.2
7.1
58
272
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.1
7.1
66
326
A28
ICPC
Limited function/disability NOS
1.9
7.1
90
497
H02AB09
ATC
hydrocortisone; systemic
3.7
7.1
22
61
R06AE07
ATC
cetirizine; oral
1.5
7.1
343
2663
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.6
7.0
193
1323
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
2.5
7.0
42
171
R03DC03
ATC
montelukast; oral
1.7
7.0
135
846
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
2.1
7.0
64
314
C08CA02
ATC
felodipine; oral
2.2
7.0
57
267
H01
ICPC
Ear pain/earache
1.8
6.9
100
575
L30.3
ICD-10 Finland
Infective dermatitis
2.8
6.9
34
125
F32.9
ICD-10 Finland
Depressive episode, unspecified
1.8
6.9
113
675
N18.8
ICD-10 Finland
Other chronic renal failure
4.0
6.9
19
48
A02BC01
ATC
omeprazole; systemic
1.6
6.9
191
1311
A07AA02
ATC
nystatin; oral
2.6
6.9
38
149
R03BA08
ATC
ciclesonide; inhalant
2.0
6.9
71
365
SPA00
NOMESCO Finland
Changing form of teeth in prepation for prosthodontic work
2.8
6.8
34
126
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.5
6.8
347
2713
UJF32
NOMESCO Finland
Coloscopy
1.6
6.8
174
1172
L73.8
ICD-10 Finland
Other specified follicular disorders
6.2
6.8
17
28
J01MA14
ATC
moxifloxacin; systemic
2.1
6.8
67
339
Z01.0
ICD-10 Finland
Examination of eyes and vision
1.7
6.7
129
807
L04AA17
ATC
[U] adalimumab
22.7
6.7
9
*
R03AC02
ATC
salbutamol; inhalant
1.5
6.7
435
3563
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
2.8
6.7
33
122
D07XC01
ATC
betamethasone; topical
1.9
6.6
92
523
H04.10
ICD-10 Finland
Dry eye syndrome
1.9
6.6
85
471
E000001, ,
ATC
1.6
6.6
156
1030
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
3.4
6.6
23
69
D07BC01
ATC
betamethasone and antiseptics; topical
1.9
6.5
89
503
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
1.9
6.5
77
415
N05AH04
ATC
quetiapine; oral
1.6
6.5
149
978
C07AB07
ATC
bisoprolol; oral
1.5
6.4
299
2294
N06AB04
ATC
citalopram; systemic
1.6
6.4
151
998
I50.9
ICD-10 Finland
Heart failure, unspecified
2.0
6.4
67
347
J45.0
ICD-10 Finland
Predominantly allergic asthma
1.9
6.4
78
426
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
2.4
6.3
43
186
JN3AD
NOMESCO Finland
Abdominal CT examination
1.9
6.3
85
478
L88
ICPC
Rheumatoid/seropositive arthritis
2.7
6.3
32
120
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.5
6.3
246
1818
E66.00
ICD-10 Finland
Metabolic syndrome
2.3
6.3
48
219
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
2.5
6.3
38
156
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
3.1
6.3
26
87
M05BA04
ATC
alendronic acid; oral
2.4
6.2
43
188
P01BA02
ATC
hydroxychloroquine; oral
2.0
6.2
63
322
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
4.0
6.2
17
43
R60.9
ICD-10 Finland
Oedema, unspecified
2.6
6.2
35
139
J01FA10
ATC
azithromycin; systemic
1.4
6.2
473
3970
L04AA13
ATC
[U] leflunomide
3.3
6.2
22
67
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
2.0
6.1
62
316
A12AA04
ATC
calcium carbonate; oral
4.2
6.1
16
39
Z3226
NOMESCO Finland
Physiotherapist
1.7
6.1
132
852
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
3.1
6.1
24
78
AA1AD
NOMESCO Finland
CT of head and brain
1.6
6.1
170
1168
A05AA02
ATC
ursodeoxycholic acid; oral
3.6
6.1
19
53
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
6.8
6.1
14
21
A46
ICD-10 Finland
Erysipelas
1.8
6.0
94
554
N05BA01
ATC
diazepam; systemic, rectal
1.8
6.0
94
554
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
1.8
6.0
85
486
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
2.6
6.0
34
135
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
461
3163
2.02
21.59
10.5
6.0
2.80
2.83
%
0.09
440
2978
530
3849
2.02
20.80
14.4
9.2
4.11
4.03
e9/l
0.34
477
3380
470
3291
1.97
20.27
10.4
6.0
28.74
28.66
%
0.05
450
3114
464
3240
1.97
20.12
10.1
5.8
57.09
56.66
%
0.34
442
3061
177
919
2.17
17.11
2.7
1.8
—
—
—
0
0
627
5019
1.99
16.40
11.0
7.3
74.49
76.41
u/l
0.58
605
4739
33
68
5.01
15.32
1.4
1.3
—
—
—
0
0
365
2514
1.80
15.02
6.7
5.1
35.99
36.42
g/l
0.73
342
2375
440
3270
1.73
13.36
7.6
6.4
10.73
11.07
umol/l
0.46
418
3107
399
2916
1.70
12.64
10.2
7.0
1.21
1.21
mmol/l
0.11
350
2501
321
2211
1.73
12.64
4.6
3.0
—
—
—
0
0
479
3681
1.70
12.54
6.6
5.0
6.71
6.60
mmol/l
0.48
454
3398
363
2601
1.70
12.27
3.0
2.3
72.94
74.21
nmol/l
0.38
333
2373
366
2633
1.69
12.15
8.9
6.3
1.21
1.21
mmol/l
0.05
339
2431
98
457
2.30
12.11
1.5
1.2
170.89
170.35
u/ml
0.00
92
420
366
2650
1.68
11.75
11.8
11.2
1.11
1.19
inr
2.02
127
825
527
4213
1.67
11.36
5.6
3.8
89.80
351.02
e6/l
—
5
56
103
513
2.15
10.82
3.5
2.5
10.50
10.37
g/l
0.11
94
475
46
158
3.02
10.50
10.4
6.6
274.00
427.96
iu/ml
—
7
23
589
4899
1.68
10.41
7.2
3.8
11.70
10.13
mm/h
1.87
564
4560
283
1969
1.66
10.26
3.9
2.6
54.33
59.24
u/l
1.02
260
1842
163
973
1.84
10.17
5.8
3.5
0.82
0.82
mmol/l
0.30
157
930
116
625
1.99
9.85
2.3
2.0
380.52
371.74
nmol/l
0.10
99
583
27
69
4.01
9.65
1.8
1.7
—
—
—
0
0
274
1929
1.62
9.30
3.9
3.2
7.55
8.35
mmol/l
2.08
231
1659
84
411
2.16
9.21
2.4
1.6
—
—
—
0
0
256
1786
1.62
8.96
3.3
2.1
153.17
274.30
u/l
1.46
243
1697
80
389
2.17
8.91
4.1
2.9
195.03
174.10
ng/l
0.21
70
342
114
632
1.93
8.89
2.5
1.8
—
—
—
0
0
263
1857
1.61
8.72
4.1
3.0
30.44
78.75
e6/l
0.73
208
1402
601
5131
1.60
8.51
4.3
3.8
14.57
14.55
pmol/l
0.05
548
4721
191
1253
1.68
8.45
3.9
2.4
3.79
6.18
e6/l
2.20
176
1113
213
1443
1.64
8.30
1.6
1.4
2.17
2.34
g/l
0.87
133
933
412
3246
1.53
8.29
5.9
4.3
0.00
0.00
estimate
0.50
86
625
237
1651
1.61
8.24
3.6
2.6
965.33
5398.84
umol/l
3.22
215
1485
414
3276
1.52
8.10
4.7
3.2
0.00
0.01
estimate
0.80
80
599
210
1428
1.63
8.03
3.6
3.0
1534.68
1011.60
ng/l
0.84
188
1194
240
1687
1.59
8.00
4.0
2.8
0.45
0.38
e6/l
0.18
186
1247
23
61
3.85
7.84
1.9
1.8
—
—
—
0
0
110
629
1.86
7.78
2.5
1.8
—
—
—
0
0
148
926
1.73
7.75
3.5
2.4
12.34
14.11
umol/l
2.29
141
876
308
2306
1.53
7.70
4.3
3.4
31.41
31.97
u/l
0.13
293
2202
54
238
2.36
7.61
1.9
1.5
3.14
0.06
iu/ml
0.96
12
43
407
3243
1.50
7.50
4.6
3.2
0.00
0.00
estimate
0.50
89
647
696
6229
1.69
7.46
5.1
4.4
1.86
2.21
mu/l
0.70
644
5797
130
792
1.76
7.46
3.7
2.5
23.26
24.50
%
0.40
107
698
158
1017
1.68
7.43
3.0
2.5
0.63
1.08
e6/l
1.63
88
553
100
564
1.88
7.38
2.3
2.5
0.21
0.22
g/l
0.64
90
532
169
1114
1.65
7.24
4.8
3.4
142.46
629.29
ng/l
2.34
117
787
52
231
2.33
7.21
2.9
1.8
—
—
—
0
0
596
5161
1.53
7.16
3.5
3.4
—
—
—
0
0
234
1676
1.55
7.06
4.1
3.4
765.43
292.85
mg/l
0.58
161
1111
136
852
1.71
7.06
3.5
2.4
2.33
2.36
g/l
0.30
129
800
264
1945
1.52
6.98
3.6
3.3
2.34
2.35
mmol/l
0.43
236
1759
244
1770
1.53
6.93
4.5
4.0
9.52
9.45
mg/mmol
0.01
161
1144
382
3038
1.47
6.92
3.4
2.8
112.27
113.17
ug/l
0.03
359
2849
90
501
1.89
6.91
6.2
4.0
2.19
1.80
mmol/l
0.55
76
409
108
639
1.79
6.83
6.1
9.3
0.99
0.92
mmol/l
0.07
91
519
82
445
1.93
6.80
2.3
2.3
5.59
8.16
ug/l
0.96
74
400
37
144
2.64
6.78
3.2
1.7
—
—
—
0
0
26
83
3.20
6.76
3.3
1.6
—
—
—
0
0
77
410
1.97
6.75
6.9
4.1
117.75
81.75
ng/l
1.06
70
371
63
312
2.10
6.72
3.2
2.1
35.71
38.14
u/l
0.57
56
283
305
2330
1.49
6.72
2.0
1.9
94.35
94.85
pmol/l
0.06
161
1267
49
219
2.31
6.71
2.8
1.7
—
—
—
0
0
297
2274
1.47
6.40
4.1
3.2
56.98
38.50
ng/l
0.42
183
1382
749
6907
1.79
6.37
21.8
12.1
18.50
22.22
mg/l
3.36
620
5357
209
1503
1.52
6.07
2.0
1.8
0.79
1.05
mg/l
1.76
149
1103
27
95
2.90
5.99
2.4
1.5
—
—
—
0
0
41
180
2.34
5.87
3.7
2.7
—
—
—
0
0
88
514
1.80
5.81
1.3
1.2
106.61
152.60
iu/ml
0.67
31
208
120
765
1.66
5.80
2.9
2.9
6.34
8.06
umol/l
0.86
98
676
24
81
3.02
5.72
3.4
1.6
—
—
—
0
0
229
1697
1.48
5.71
5.6
3.5
0.00
0.01
estimate
1.08
86
608
167
1160
1.55
5.66
1.4
1.3
30.26
31.62
iu/ml
0.05
65
371
74
415
1.86
5.57
2.1
2.9
66.88
67.14
g/l
0.13
69
388
29
111
2.67
5.53
3.3
1.6
—
—
—
0
0
73
412
1.85
5.40
2.4
3.5
4.41
4.59
pmol/l
1.05
61
372
27
101
2.73
5.38
3.6
1.7
—
—
—
0
0
42
194
2.23
5.37
1.3
1.2
—
1.13
—
0
7
48
235
2.11
5.32
2.6
1.7
—
—
—
0
0
40
182
2.26
5.30
1.3
1.2
2.17
11.57
u/ml
—
6
28
142
967
1.56
5.23
2.9
2.7
3.73
2.05
e6/l
0.95
72
511
317
2534
1.40
5.15
4.8
3.2
—
—
—
0
0
210
1558
1.46
5.14
2.4
2.2
—
—
—
0
0
64
352
1.89
5.13
5.4
3.3
1.93
1.76
mmol/l
0.12
40
249
203
1499
1.47
5.09
2.5
2.1
2.96
2.88
mg/l
0.14
176
1289
219
1642
1.45
5.07
1.3
1.2
2.30
1.50
u/ml
0.20
51
454
22
76
2.95
5.06
3.1
1.8
—
—
—
0
0
22
76
2.95
5.06
3.1
1.8
—
—
—
0
0
34
148
2.35
5.00
3.4
1.7
—
—
—
0
0
182
1321
1.48
4.96
1.6
1.5
19.79
20.60
nmol/l
0.32
159
1150
738
6866
1.62
4.95
21.7
13.4
139.46
139.66
mmol/l
1.44
725
6694
18
56
3.26
4.91
1.9
1.2
9851.69
10354.74
e6/l
0.03
13
39
66
373
1.84
4.87
5.5
3.2
5.18
5.09
kpa
0.31
60
360
10
13
7.77
4.86
5.6
5.1
—
—
—
0
0
135
924
1.55
4.85
3.3
2.5
129.74
105.70
ug/g
0.37
113
736
22
78
2.87
4.85
1.0
1.1
—
—
—
0
0
27
107
2.57
4.83
1.1
1.4
—
—
—
0
0
27
107
2.57
4.83
1.1
1.4
—
—
—
0
0
193
1427
1.46
4.78
5.4
3.4
1.01
1.02
kg/l
1.34
25
201
27
108
2.55
4.75
3.1
1.8
—
—
—
0
0
27
108
2.55
4.75
3.1
1.8
—
—
—
0
0
739
6896
1.60
4.68
21.9
13.5
3.97
3.95
mmol/l
1.47
722
6711
22
80
2.80
4.64
2.6
1.5
—
—
—
0
0
158
1133
1.49
4.55
1.4
1.3
21.28
10.23
u/ml
0.76
56
459
43
215
2.05
4.54
2.5
2.1
—
—
—
0
0
58
322
1.86
4.54
1.9
1.6
—
—
—
0
0
21
78
2.74
4.28
1.0
1.1
—
—
—
0
0
19
67
2.88
4.25
1.0
1.1
—
—
—
0
0
8
10
8.06
4.06
4.4
2.6
—
—
—
0
0
17
58
2.97
4.03
2.3
1.2
—
—
—
0
0
39
198
2.02
3.98
1.9
2.2
—
—
—
0
0
17
59
2.92
3.91
2.3
1.3
—
—
—
0
0
17
59
2.92
3.91
1.1
1.2
—
—
—
0
0
16
54
3.00
3.86
1.6
1.2
1.15
0.43
u/ml
—
10
31
696
6474
1.44
3.84
17.0
10.7
87.63
87.91
ml/min/173m2
0.12
595
5292
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
33
161
2.09
3.76
1.9
2.7
0.20
0.35
u/ml
2.31
17
79
31
148
2.14
3.73
1.5
1.2
—
—
—
0
0
32
155
2.11
3.71
1.1
1.2
11.73
38.13
u/ml
—
6
12
29
135
2.19
3.71
2.2
1.5
18084.33
10246.98
e6/l
0.32
24
104
17
61
2.82
3.70
3.2
3.6
—
—
—
0
0
813
7856
2.13
3.67
30.1
17.7
257.42
253.03
e9/l
1.17
805
7688
9
16
5.67
3.66
4.2
4.6
—
—
—
0
0
658
6078
1.38
3.63
6.4
5.1
39.95
39.09
mmol/mol
1.30
620
5722
774
7379
1.63
3.58
15.4
9.5
28.53
28.03
u/l
0.23
763
7168
813
7863
2.10
3.54
30.1
17.6
4.56
4.58
e12/l
0.59
803
7681
201
1573
1.37
3.50
1.7
1.6
—
—
—
0
0
31
152
2.08
3.50
1.8
1.3
—
—
—
0
0
76
493
1.60
3.46
2.8
2.3
8.44
22.14
au/ml
—
5
43
813
7868
2.07
3.45
30.2
17.7
137.35
137.98
g/l
0.60
805
7782
812
7857
2.04
3.41
30.1
17.8
46.73
40.85
%
0.52
772
7445
17
64
2.69
3.41
1.0
1.1
—
—
—
0
0
17
64
2.69
3.41
1.0
1.1
—
—
—
0
0
17
65
2.65
3.32
1.0
1.1
—
—
—
0
0
17
65
2.65
3.32
1.0
1.1
—
—
—
0
0
17
65
2.65
3.32
1.0
1.1
—
—
—
0
0
14
49
2.89
3.20
1.2
1.0
—
—
—
0
0
60
375
1.65
3.19
2.8
2.2
8767.89
3446.95
u/l
0.40
21
155
42
238
1.81
3.15
2.8
1.9
2.79
2.46
ug/l
0.07
37
221
24
111
2.20
3.15
1.5
1.5
—
—
—
0
0
15
56
2.71
3.07
2.2
1.6
—
—
—
0
0
15
56
2.71
3.07
2.2
1.6
—
—
—
0
0
15
56
2.71
3.07
2.2
1.6
—
—
—
0
0
25
120
2.12
3.01
3.6
2.4
128.00
131.49
g/l
0.27
17
86
15
57
2.66
2.97
7.0
9.5
9.23
6.87
mmol/l
—
10
45
157
1213
1.36
2.94
1.7
1.6
179856522.90
18762325.25
pmol/l
0.88
139
1050
27
135
2.03
2.93
5.8
3.8
59.78
56.30
%
0.76
27
135
6
9
6.70
2.87
13.5
4.8
4.12
7.23
mmol/l
—
6
9
50
307
1.67
2.86
6.4
11.7
24.27
24.42
mmol/l
0.14
50
302
19
83
2.32
2.86
1.8
1.5
—
—
—
0
0
361
3138
1.26
2.81
2.9
2.5
—
—
—
0
0
26
132
2.00
2.73
4.6
3.6
4.23
4.19
e9/l
0.04
26
132
540
4931
1.27
2.72
4.1
3.0
54.93
44.93
u/l
1.39
517
4680
19
85
2.26
2.72
1.8
1.5
—
—
—
0
0
19
85
2.26
2.72
1.8
1.5
—
—
—
0
0
125
943
1.38
2.72
1.8
1.6
1236.75
1154.88
nmol/l
0.37
95
746
31
168
1.88
2.70
1.6
1.2
302.96
220.01
u/ml
0.59
23
104
61
401
1.56
2.67
1.6
1.4
24.26
22.92
iu/l
0.14
50
338
12
43
2.82
2.65
3.0
2.9
—
—
—
0
0
98
712
1.43
2.65
7.4
6.0
—
—
—
0
0
20
93
2.18
2.62
1.2
1.3
—
—
—
0
0
40
240
1.70
2.52
6.0
3.7
24.56
25.11
mmol/l
0.51
34
231
9
26
3.49
2.48
2.1
1.3
—
—
—
0
0
55
360
1.56
2.47
1.5
1.4
—
—
—
0
0
13
51
2.57
2.45
1.3
1.3
—
—
—
0
0
28
153
1.86
2.41
2.1
1.5
87.85
106.67
u/ml
0.55
11
31
31
176
1.79
2.37
1.6
1.2
—
—
—
0
0
8
22
3.66
2.37
2.3
1.4
—
—
—
0
0
18
84
2.17
2.36
1.8
1.5
—
—
—
0
0
723
6899
1.35
2.33
5.0
4.3
2.73
2.83
mmol/l
2.10
685
6480
15
65
2.33
2.32
4.5
1.8
—
—
—
0
0
18
85
2.14
2.30
1.8
1.5
—
—
—
0
0
18
85
2.14
2.30
1.8
1.5
—
—
—
0
0
22
114
1.95
2.22
1.1
1.1
—
—
—
0
0
36
219
1.67
2.19
1.6
1.3
—
—
—
0
0
24
129
1.89
2.18
1.3
1.1
—
—
—
0
0
686
6514
1.29
2.17
4.6
4.0
5.95
5.86
mmol/l
0.86
632
6041
6
14
4.31
2.15
1.0
1.0
—
—
—
0
0
8
25
3.22
2.10
4.6
1.7
—
—
—
0
0
11
43
2.58
2.08
1.3
1.1
1.03
1.07
u/l
—
6
24
22
117
1.90
2.08
4.0
1.6
—
—
—
0
0
8
26
3.10
2.01
4.1
2.2
55.88
90.87
ug/l
—
8
26
9
32
2.83
2.00
1.0
1.4
—
—
—
0
0
9
32
2.83
2.00
1.0
1.4
—
—
—
0
0
42
274
1.56
1.96
1.4
1.4
—
—
—
0
0
27
157
1.74
1.94
2.7
2.3
22.85
109.28
ug/min
1.85
17
92
6
16
3.77
1.93
1.2
1.3
—
—
—
0
0
80
595
1.38
1.93
4.8
2.9
—
—
—
0
0
9
33
2.75
1.93
1.0
1.1
2075.56
1640.39
miu/ml
—
9
33
124
986
1.30
1.92
2.8
2.8
2.42
2.43
mmol/l
0.50
106
872
16
78
2.07
1.92
1.4
1.2
—
—
—
0
0
12
52
2.33
1.88
1.8
2.7
—
—
—
0
0
712
6823
1.29
1.88
4.6
4.0
4.56
4.70
mmol/l
3.57
682
6445
9
34
2.66
1.87
1.4
1.7
—
1224630.00
iu/ml
—
0
5
28
167
1.70
1.86
1.2
1.1
0.55
2.72
u/ml
2.17
14
89
7
24
2.93
1.72
2.4
1.3
—
—
—
0
0
7
24
2.93
1.72
1.0
2.7
228.86
188.71
u/l
—
7
24
40
267
1.52
1.72
5.7
2.9
0.59
0.65
%
0.99
40
267
40
267
1.52
1.72
1.5
1.4
8.64
8.81
u/l
0.03
30
218
79
603
1.34
1.65
2.4
2.2
13.67
13.51
nmol/l
0.05
71
554
11
49
2.26
1.64
1.6
1.4
—
—
—
0
0
80
613
1.34
1.63
3.5
2.5
34.79
115.31
u/l
0.53
71
528
7
26
2.71
1.58
1.3
1.7
—
—
—
0
0
11
50
2.22
1.57
1.1
1.0
—
—
—
0
0
35
233
1.52
1.54
1.7
1.6
—
—
—
0
0
202
1744
1.21
1.54
1.7
1.7
1.45
1.41
mmol/l
0.31
172
1502
33
217
1.54
1.53
1.3
1.1
—
—
—
0
0
66
497
1.36
1.52
3.7
2.5
70.67
73.33
ml/min/173m2
0.17
27
198
9
37
2.45
1.48
3.2
2.6
488.00
699.73
u/ml
—
9
37
705
6792
1.24
1.48
4.5
4.0
1.40
1.43
mmol/l
1.50
670
6395
240
2113
1.19
1.47
4.5
4.3
1.88
2.18
ug/l
0.50
218
1914
45
320
1.43
1.45
4.0
2.7
0.54
0.11
e6/l
0.72
45
311
11
52
2.13
1.45
1.6
1.4
—
—
—
0
0
22
133
1.67
1.43
4.2
3.8
13.63
27.54
mg/l
2.32
12
85
9
39
2.32
1.43
1.0
1.2
—
—
—
0
0
24
149
1.63
1.42
1.9
4.2
80.38
32.93
mg/l
0.57
19
125
24
149
1.63
1.42
1.9
4.2
48.94
92.69
mg/l
0.51
18
125
681
6547
1.21
1.40
4.2
3.6
1.37
1.30
mmol/l
1.57
642
6141
24
150
1.62
1.39
1.8
1.4
—
—
—
0
0
6
23
2.62
1.37
1.7
2.1
—
—
—
0
0
30
201
1.51
1.31
1.2
1.2
—
—
—
0
0
34
234
1.47
1.31
1.9
2.3
97.18
90.95
%
1.10
34
223
30
203
1.50
1.26
1.2
1.2
—
—
—
0
0
9
45
2.01
1.23
2.3
3.0
39752.33
41231.11
ug/l
—
9
45
12
63
1.92
1.23
1.2
1.5
0.89
1.00
g/l
0.57
12
63
10
49
2.05
1.22
1.4
1.5
71.80
76.67
umol/l
—
10
49
5
19
2.64
1.21
1.2
1.2
—
—
—
0
0
640
6145
1.17
1.20
23.9
14.5
14.92
14.43
%
1.31
634
6049
25
165
1.53
1.18
1.5
1.5
279.46
294.19
ug/g
0.13
14
101
20
125
1.61
1.18
1.1
1.1
112.63
107.44
iu/ml
—
8
33
57
440
1.32
1.16
7.0
3.7
1.23
1.22
mmol/l
0.20
47
389
8
39
2.06
1.15
1.0
1.1
186.96
161.08
iu/ml
—
8
39
5
20
2.51
1.15
1.2
1.2
—
—
—
0
0
5
20
2.51
1.15
1.2
1.3
—
—
—
0
0
5
20
2.51
1.15
1.2
1.3
—
—
—
0
0
46
345
1.35
1.13
1.8
1.6
306.34
309.33
mu/l
0.02
38
316
23
151
1.54
1.12
1.1
1.6
2.80
11.06
e6/l
1.05
15
120
23
151
1.54
1.12
1.2
1.6
176.69
1272.40
e6/l
0.69
16
124
10
51
1.97
1.11
5.0
1.9
—
—
—
0
0
190
1681
1.17
1.09
4.1
3.7
21.75
21.27
%
0.15
74
722
30
212
1.43
1.05
2.0
2.5
171.97
174.34
%
0.05
30
202
12
67
1.80
1.05
1.8
1.1
—
—
—
0
0
7
34
2.07
1.03
1.1
1.4
—
24.33
—
0
6
28
197
1.44
1.01
4.7
4.1
1.31
1.33
mmol/l
0.04
28
191
9
48
1.88
1.00
2.1
1.9
—
—
—
0
0
5
23
2.18
0.98
1.0
1.0
110.28
26.75
u/ml
—
5
23
17
108
1.59
0.97
4.2
2.2
15.76
16.56
%
—
10
49
17
108
1.59
0.97
3.5
2.2
6.86
7.10
umol/l
0.03
11
77
9
50
1.81
0.97
1.6
1.5
—
—
—
0
0
9
51
1.77
0.94
1.0
1.3
1.48
1.55
g/l
—
9
51
9
52
1.74
0.92
2.7
2.7
—
—
—
0
0
11
63
1.76
0.90
3.1
1.6
—
—
—
0
0
6
30
2.01
0.87
2.2
1.4
10.17
15.73
u/l
—
6
30
52
417
1.26
0.84
1.6
1.4
—
—
—
0
0
18
121
1.50
0.83
1.6
1.8
—
—
—
0
0
17
113
1.51
0.82
3.4
1.9
6.80
5.29
mmol/24h
0.90
17
100
64
530
1.22
0.79
3.1
4.4
2.77
32.79
ug/l
1.22
47
434
23
165
1.41
0.78
1.8
1.6
—
—
—
0
0
20
140
1.44
0.77
1.3
1.1
0.66
1.85
u/ml
—
10
71
13
83
1.58
0.75
2.0
1.3
0.57
0.57
nmol/l
0.00
13
78
5
24
2.09
0.74
1.2
1.0
—
—
—
0
0
7
39
1.80
0.72
2.1
1.5
1.86
6.51
u/l
—
7
33
7
40
1.76
0.71
4.4
1.5
—
—
—
0
0
5
26
1.93
0.70
1.2
1.2
—
—
—
0
0
5
26
1.93
0.70
1.0
1.3
74.80
122.67
nmol/l
—
5
19
25
186
1.35
0.70
2.0
1.8
223.56
220.56
pmol/l
0.03
25
176
11
69
1.60
0.68
1.1
1.1
—
—
—
0
0
7
119
0.58
0.68
1.4
1.2
—
—
—
0
0
86
747
1.17
0.66
4.3
4.1
30.86
31.05
%
0.06
69
538
17
120
1.43
0.65
1.2
1.0
0.79
1.94
u/ml
—
7
57
16
112
1.44
0.64
4.6
5.8
348.49
365.36
umol/l
0.16
16
99
78
677
1.17
0.62
1.9
1.9
—
—
—
0
0
32
253
1.28
0.62
1.3
1.4
—
—
—
0
0
5
30
1.67
0.61
1.0
1.9
—
74.17
%
—
0
6
21
278
0.75
0.61
1.3
1.4
—
—
—
0
0
127
1144
1.13
0.60
1.7
1.5
—
—
—
0
0
21
277
0.75
0.60
1.3
1.4
—
—
—
0
0
21
276
0.75
0.59
1.2
1.4
—
—
—
0
0
21
276
0.75
0.59
1.2
1.4
—
—
—
0
0
8
53
1.51
0.58
1.0
1.2
—
—
—
0
0
6
36
1.67
0.56
1.2
1.1
—
—
—
0
0
137
1246
1.12
0.56
2.2
2.1
—
—
—
0
0
39
321
1.23
0.55
2.8
2.5
38.18
39.53
u/ml
0.03
39
309
23
295
0.77
0.55
1.3
1.4
—
—
—
0
0
29
232
1.26
0.53
1.4
1.5
—
—
—
0
0
10
66
1.52
0.52
4.6
2.3
14.80
22.08
mg/l
—
5
16
24
188
1.28
0.51
1.6
1.8
4.40
5.42
iu/l
—
6
59
18
135
1.34
0.51
1.1
1.5
0.48
0.37
nmol/l
0.34
13
112
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
41
1.47
0.50
1.2
1.1
—
—
—
0
0
124
1131
1.11
0.49
2.2
2.0
—
—
—
0
0
137
1258
1.11
0.48
2.9
2.7
0.59
0.73
ug/l
1.83
85
763
7
51
1.38
0.44
1.3
1.2
—
—
—
0
0
5
31
1.62
0.43
1.0
1.4
—
—
—
0
0
5
31
1.62
0.43
1.0
1.4
—
—
—
0
0
8
56
1.43
0.42
1.0
1.1
—
—
—
0
0
5
33
1.52
0.41
2.8
1.6
—
—
—
0
0
5
33
1.52
0.41
2.8
1.6
—
—
—
0
0
19
150
1.27
0.40
1.2
1.2
—
—
—
0
0
5
34
1.47
0.40
1.0
1.1
102.00
26.79
u/l
—
5
34
5
34
1.47
0.40
1.0
1.1
255.40
85.15
u/l
—
5
34
5
35
1.43
0.39
5.8
1.5
—
—
—
0
0
9
68
1.33
0.37
1.0
1.0
—
—
—
0
0
16
125
1.29
0.37
1.2
1.4
13.11
22.11
u/l
—
10
104
115
1066
1.09
0.36
1.9
1.8
1.50
1.45
%
0.37
104
959
60
538
1.12
0.35
2.0
1.8
—
—
—
0
0
11
82
1.35
0.34
1.7
2.3
—
—
—
0
0
73
799
0.91
0.32
1.5
1.7
—
—
—
0
0
29
331
0.87
0.26
1.6
1.4
—
—
—
0
0
11
87
1.27
0.24
1.0
1.1
112.09
97.13
%
1.17
11
80
20
171
1.17
0.23
1.6
1.5
—
—
—
0
0
14
116
1.21
0.22
1.1
1.1
125.57
117.60
%
0.44
14
106
5
41
1.22
0.22
1.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.8
—
0.36
—
0
11
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
14
117
1.20
0.20
1.2
1.1
—
—
—
0
0
13
155
0.84
0.20
2.1
1.9
—
—
—
0
0
11
91
1.21
0.17
1.0
1.1
—
—
—
0
0
14
121
1.16
0.15
1.3
1.2
1.14
3.63
u/ml
—
7
43
11
128
0.86
0.13
2.0
1.5
—
—
—
0
0
41
388
1.06
0.10
1.1
1.0
—
—
—
0
0
17
154
1.11
0.10
5.1
2.4
0.79
0.87
nmol/l
0.22
17
132
47
493
0.95
0.09
1.5
1.5
—
—
—
0
0
5
63
0.79
0.08
1.0
1.4
123.98
174.71
pmol/l
—
5
63
32
303
1.06
0.08
1.4
1.3
192.07
237.59
miu/ml
0.30
14
154
28
266
1.05
0.06
1.7
1.7
—
—
—
0
0
13
122
1.07
0.02
1.0
1.1
—
—
—
0
0
21
205
1.03
0.00
1.6
1.7
—
—
—
0
0
33
325
1.02
0.00
1.7
1.9
—
—
—
0
0
34
341
1.00
0.00
1.6
1.7
3.83
3.30
mg/l
0.14
27
249
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
7
72
0.97
0.00
1.9
2.4
106.00
105.68
mmol/l
—
7
72
0
8
0.00
0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
14.00
—
0
6
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint AB1_OTHER_SUPERF_MYCOSIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| AB1_OTHER_SUPERF_MYCOSIS | 1.458 [1.17, 1.82] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.101 |
During the follow-up period (1.1.1998 — 31.12.2019), 162 out of 1804 females with AB1_OTHER_SUPERF_MYCOSIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| AB1_OTHER_SUPERF_MYCOSIS | 1.789 [1.46, 2.2] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.005 |
During the follow-up period (1.1.1998 — 31.12.2019), 270 out of 1925 males with AB1_OTHER_SUPERF_MYCOSIS died.
Mortality risk
Mortality risk for people of age
years, who have AB1_OTHER_SUPERF_MYCOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.135% | 0.398% |
| 5 | 0.8% | 2.169% |
| 10 | 2.085% | 5.0% |
| 15 | 4.018% | 9.478% |
| 20 | 7.086% | 15.894% |
Relationships between endpoints
↥Index endpoint: AB1_OTHER_SUPERF_MYCOSIS – Other superficial mycoses
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data